Lee Hartner, MD

Elghawy O, Stylli J, Kurian M, Halper-Stromberg E, Singh A, D'Avella C, Hartner L, Cohen RB Clinicogenomic Features and Outcomes of Adenoid Cystic Carcinoma With Central Nervous System Metastases: A Single-Institution Cohort Study , Head and Neck: 2026

Aleixo G, Hartner L, Diamond M, Wong W, Allen JW, Yi I, Costa P, Lefler DS Liposomal Versus Conventional Doxorubicin as First-Line Therapy in Advanced Soft Tissue Sarcomas: Observational Multi-Institutional Cohort of 8.5-Year Experience , Journal of Clinical Oncology Practice: 2026,OP2600132

Kam AE, Zhao F, Meropol NJ, Giantonio BJ, Diasio RB, Flynn PJ, Catalano P, Hartner L, Rowland KM, Song W, Mulcahy MF, Sinicrope FA, Whitehead RP, Mayer RJ, Petrelli N, O'Dwyer PJ, Hamilton SR, Cella D, Benson AB Intergroup randomized phase III study of adjuvant FOLFIRI, FOLFOX, or 5-FU/leucovorin for stage II/III rectal cancer: ECOG-ACRIN E3201 , Oncologist, 31(1): 2025

Mowery YM, Ballman KV, Hong AM, Schuetze SM, Wagner AJ, Monga V, Heise RS, Attia S, Choy E, Burgess MA, Bae S, Pryor DI, Van Tine BA, Tinoco G, Chmielowski B, Freeman C, Gronchi A, Meyer CF, Dickson MA, Hartner L, Davis LE, Powers BC, Moding EJ, Weinhold KJ, van de Rijn M, Brigman BE, Riedel RF, Kirsch DG Safety and efficacy of pembrolizumab, radiation therapy, and surgery versus radiation therapy and surgery for stage III soft tissue sarcoma of the extremity (SU2C-SARC032): an open-label, randomised clinical trial , Lancet, 404(10467): 2024,2053-2064

Loggers ET, Chugh R, Federman N, Hartner L, Riedel RF, Cho S, Hyslop D, Lim A, Oton AB, Oktay KH Onset and resolution of ovarian toxicity with nirogacestat treatment in females with desmoid tumors: Updated safety analyses from the DeFi phase 3 study , Cancer, 130(16): 2024,2812-2821

Van Tine B, Eulo V, Toeniskoetter J, Ruff T, Luo J, Kemp L, Tellez CM, Weiss MC, Hirbe AC, Meyer CF, Elias AD, Diamond M, Hartner LP, Bui N, Ganjoo KN, Maki RG, Wilky BA RANDOMIZED PHASE II TRIAL OF CABOZANTINIB COMBINED WITH PD-1 AND CTLA-4 INHIBITION VERSUS CABOZANTINIB IN METASTATIC SOFT TISSUE SARCOMA. , CTOS Annual Meeting: 2023

Chugh R, Chawla SP, Spira A, Subbiah V, Hartner L, Wilky BA, Lakhani N, Lieu, C, Ratan R, O'Neill B, Andrianov V, Piccione E, Kalabus J, Willis KM, Eckelman B, Grohar P THE TETRAVALENT DEATH RECEPTOR 5 AGONIST INBRX-109 COMBINED WITH CHEMOTHERAPY IN EWING SARCOMA: PRELIMINARY DATA FROM A PHASE 1 STUDY , CTOS Annual Meeting: 2023

Gounder M, Ratan R, Alcindor T, Schöffski P, van der Graaf WT, Wilky BA, Riedel RF, Lim A, Smith LM, Moody S, Attia S, Chawla S, D'Amato G, Federman N, Merriam P, Van Tine BA, Vincenzi B, Benson C, Bui NQ, Chugh R, Tinoco G, Charlson J, Dileo P, Hartner L, Lapeire L, Mazzeo F, Palmerini E, Reichardt P, Stacchiotti S, Bailey HH, Burgess MA, Cote GM, Davis LE, Deshpande H, Gelderblom H, Grignani G, Loggers E, Philip T, Pressey JG, Kummar S, Kasper B Nirogacestat, a γ-Secretase Inhibitor for Desmoid Tumors. , New England Journal of Medcine, 388(10): 2023,898-921

Jia H, Roberson D, Luo X, Kovell RC, Hartner L, Harryhill JF Primary follicular lymphoma of the prostate presenting with elevated PSA and a PI-RADS 3 lesion on MRI: A case report , Urology Case Reports, 45: 2022,102195

Gounder MM, Razak AA, Somaiah N, Chawla S, Martin-Broto J, Grignani G, Schuetze SM, Vincenzi B, Wagner AJ, Chmielowski B, Jones RL, Riedel RF, Stacchiotti S, Loggers ET, Ganjoo KN, Le Cesne A, Italiano A, Garcia Del Muro X, Burgess M, Piperno-Neumann S, Ryan C, Mulcahy MF, Forscher C, Penel N, Okuno S, Elias A, Hartner L, Philip T, Alcindor T, Kasper B, Reichardt P, Lapeire L, Blay JY, Chevreau C, Valverde Morales CM, Schwartz GK, Chen JL, Deshpande H, Davis EJ, Nicholas G, Gröschel S, Hatcher H, Duffaud F, Herráez AC, Beveridge RD, Badalamenti G, Eriksson M, Meyer C, von Mehren M, Van Tine BA, Götze K, Mazzeo F, Yakobson A, Zick A, Lee A, Gonzalez AE, Napolitano A, Dickson MA, Michel D, Meng C, Li L, Liu J, Ben-Shahar O, Van Domelen DR, Walker CJ, Chang H, Landesman Y, Shah JJ, Shacham S, Kauffman MG, Attia S Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial. , J Clin Oncol., 40(22): 2022,2479-2490